Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

Recruiting now · Not applicable

Conditions studied: Chronic Kidney Diseases

In brief

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.

Key facts

Study ID: NCT04708587
Run by: Yonsei University
People needed: 900
Starts: 2021-03-23
Expected to finish: 2028-03-13
Last updated by the study team: 2026-01-21

Who can join

Age: 19 and older, up to 84. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Over 19 years old
Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR <45 / <30 / <15 or dialysis)
Patients treated with a new generation drug eluting stent.
Patients who signed consent form

You may not qualify if…

Over 85 years old
Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks
Patients who need oral anticoagulant
Pregnant women or women of childbearing age
Life expectancy is less than 1 year
Patients with a history of intracranial bleeding
Moderate to severe hepatic impairment (Child-Pugh class B or C)

Where it is running

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.